INTRODUCTION: Insulin allergy may occur in patients treated with subcutaneous applications of insulin preparations. Besides additives in the insulin preparation such as protamine, cresol, and phenol, the insulin molecule itself may be the cause of the allergy. In the latter case, therapeutic options are rare. CASE PRESENTATION: A 68-year-old man with poorly controlled type 2 diabetes mellitus received different insulin preparations subcutaneously while on oral medication. Six to eight hours after each subcutaneous application, he developed pruritic plaques with a diameter of >15 cm at the injection sites that persisted for several days. Allergologic testing revealed positive reactions against every insulin preparation and against protamine. Investigation of serum samples demonstrated IgG antibodies against human and porcine insulin. We treated the patient with human insulin using an ultra-rush protocol beginning with 0.004 IU and a rapid augmentation in dose up to 5 IU. Therapy was accompanied by antihistamine therapy. Subsequent conversion to therapy with glargine insulin (6 IE twice daily) was well-tolerated. CONCLUSION: As reported in this case, desensitization with subcutaneously administered human insulin using an ultra-rush protocol in patients with an insulin allergy may present an easy form of therapy that is successful within a few days.
INTRODUCTION:Insulin allergy may occur in patients treated with subcutaneous applications of insulin preparations. Besides additives in the insulin preparation such as protamine, cresol, and phenol, the insulin molecule itself may be the cause of the allergy. In the latter case, therapeutic options are rare. CASE PRESENTATION: A 68-year-old man with poorly controlled type 2 diabetes mellitus received different insulin preparations subcutaneously while on oral medication. Six to eight hours after each subcutaneous application, he developed pruritic plaques with a diameter of >15 cm at the injection sites that persisted for several days. Allergologic testing revealed positive reactions against every insulin preparation and against protamine. Investigation of serum samples demonstrated IgG antibodies against human and porcine insulin. We treated the patient with humaninsulin using an ultra-rush protocol beginning with 0.004 IU and a rapid augmentation in dose up to 5 IU. Therapy was accompanied by antihistamine therapy. Subsequent conversion to therapy with glargine insulin (6 IE twice daily) was well-tolerated. CONCLUSION: As reported in this case, desensitization with subcutaneously administered humaninsulin using an ultra-rush protocol in patients with an insulin allergy may present an easy form of therapy that is successful within a few days.
Authors: R Barranco; T Herrero; P Tornero; M Barrio; C Frutos; A Rodríguez; V Malvetti; M Luisa Baeza Journal: Allergy Date: 2003-06 Impact factor: 13.146
Authors: J Malaise; J Leonet; E Goffin; C Lefebvre; D Tennstedt; B Vandeleene; M Buysschaert; J P Squifflet Journal: Transplant Proc Date: 2005 Jul-Aug Impact factor: 1.066
Authors: Joselyn Rojas; Marjorie Villalobos; María Sofía Martínez; Mervin Chávez-Castillo; Wheeler Torres; José Carlos Mejías; Edgar Miquilena; Valmore Bermúdez Journal: Case Reports Immunol Date: 2014-11-19
Authors: Anh Dat Nguyen; Chinh Quoc Luong; Hieu Chi Chu; Van Khoa Dieu Nguyen; Chi Van Nguyen; Tuan Anh Nguyen; Quan Huu Nguyen; Ton Duy Mai; Dinh Van Nguyen; Bay Quang Nguyen; Thong Huu Tran; Phuong Viet Dao; Dat Tuan Nguyen; Nguyet Nhu Nguyen; Son Ngoc Do Journal: BMC Endocr Disord Date: 2019-11-11 Impact factor: 2.763